Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Additional locations may be listed on ClinicalTrials.gov for NCT05215574.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationNGM Biopharmaceuticals, Inc

• Primary ID831-IO-101
• Secondary IDsNCI-2022-01100, KEYNOTE-E13, KEYNOTE-E20
• ClinicalTrials.gov IDNCT05215574